Julie Westerlin Kjeldsen

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite et al. · Nature Medicine · 2021 · 209 citations · Full text

Medicine, Immunology, Oncology +17

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

Marco Donia, Rikke Andersen, Julie Westerlin Kjeldsen et al. · Cancer Research · 2015 · 124 citations

Life Sciences, Immunology, Oncology +17

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

Rikke Andersen, Marie Christine Wulff Westergaard, Julie Westerlin Kjeldsen et al. · Cancer Immunology Research · 2018 · 77 citations · Full text

Medicine, Immunology, Oncology +17

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

Rikke Andersen, Troels Holz Borch, Arianna Draghi et al. · Annals of Oncology · 2018 · 76 citations · Full text

Life Sciences, Immunology, Oncology +17

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Anders Kverneland, Christopher A. Chamberlain, Troels Holz Borch et al. · Journal for ImmunoTherapy of Cancer · 2021 · 69 citations · Full text

Life Sciences, Immunology, Oncology +17